Olmetec and Lactulose drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Olmetec (olmesartan medoxomil) and Lactulose (lactulose). Common drug interactions include hepatic failure among females and agranulocytosis among males.

The phase IV clinical study analyzes what interactions people have when they take Olmetec and Lactulose. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Olmetec?

Olmetec has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 7,904 Olmetec users. Check the latest studies of Olmetec.

What is Lactulose?

Lactulose has active ingredients of lactulose. It is often used in constipation. eHealthMe is studying from 46,960 Lactulose users. Check the latest studies of Lactulose.

On Jul, 13, 2026

17 people who take Olmetec and Lactulose together, and have interactions are studied.

Olmetec and Lactulose drug interactions.

What are the common drug interactions of Olmetec and Lactulose, by gender? *:

female:

Hepatic failure (liver failure)
Blood thyroid stimulating hormone increased
Cerebral haemorrhage (bleeding within the brain)
Platelet count decreased
Protein urine present
Abdominal pain upper
Gastritis (inflammation of stomach)
Malignant neoplasm progression (cancer tumour came back)
Muscular weakness (muscle weakness)
Oedema peripheral (superficial swelling)

male:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Death
Flatulence (flatus expelled through the anus)
Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hyperuricaemia (level of uric acid in the blood that is abnormally high)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Renal cyst (kidney cyst)
Renal impairment (severely reduced kidney function)

What are the common drug interactions of Olmetec and Lactulose, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
Hyperuricaemia (level of uric acid in the blood that is abnormally high)
Renal impairment (severely reduced kidney function)

50-59:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)

60+:

Decreased appetite
Hepatic failure (liver failure)
Muscular weakness (muscle weakness)
Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
Oedema peripheral (superficial swelling)
Renal cyst (kidney cyst)
Subdural haematoma (blood collects between the skull and the surface of the brain)
Blood thyroid stimulating hormone increased
Cerebral haemorrhage (bleeding within the brain)
Platelet count decreased

What are the existing conditions these people have? *

Hepatocellular Carcinoma (liver cancer): 6 people, 35.29%
Abdominal Pain Upper: 2 people, 11.76%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 11.76%
Diabetes: 2 people, 11.76%
Insomnia (sleeplessness): 2 people, 11.76%
Hepatitis (inflammation of the liver): 1 person, 5.88%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 5.88%
Gastritis - Chronic (long lasting inflammation of stomach): 1 person, 5.88%
Gastritis (inflammation of stomach): 1 person, 5.88%
Dyslipidaemia (abnormal amount of lipids): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Olmetec and Lactulose?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously